Clinical Trial Update: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avutometinib (VS-6766) in combination with defactinib in recurrent KRAS G12V, other KRAS and BRAF mutated non-small cell lung cancer ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 2 | Status: COMPLETED